

Faculty

AGNELLI LUCA Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

AMBROSINI EMILIA Politecnico di Milano, DEIB

BORACCHI GIACOMO Politecnico di Milano, DEIB

CICCHETTI ALESSANDRO Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

CRISPIN ORTUZAR MIREIA University of Cambridge

DE BRAUD FILIPPO Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

DE TOMA ALESSANDRO ASST Santi Paolo e Carlo, Ospedale San Paolo, Milano

DI MAIO MASSIMO President-elect of AIOM, University of Turin, AOU Città della Salute e della Scienza di Torino, Ospedale Molinette

FERRARA ROBERTO IRCCS Ospedale San Raffaele, Milano

GANZINELLI MONICA Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

GARASSINO MARINA CHIARA University of Chicago

GENNARI FRANCESCA Scuola Superiore Sant'Anna, Pisa

HO DEAN University of Singapore

KATHER JAKOB NIKOLAS Technical University Dresden

KOSTA SOKOL Aalborg University, Denmark

LO RUSSO GIUSEPPE Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

MAZZEO LAURA Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

MISKOVIC VANJA Politecnico di Milano, DEIB

MONZANI DARIO University of Palermo, IEO European Institute of Oncology IRCCS, Milano

PEARSON ALEXANDER T. University of Chicago

PEDROCCHI ALESSANDRA Politecnico di Milano, DEIB

PÉREZ-LOPEZ RAQUEL Vhio Radiomics Group, Barcelona

PRELAJ ARSELA Fondazione IRCCS Istituto Nazionale dei Tumori, Politecnico di Milano

PROTO CLAUDIA Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

PROVENZANO LEONARDO Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

RESELLI MARCELLO Politecnico di Milano, DEIB

SANCHEZ VEGA FRANCISCO Memorial Sloan Kettering New York

SANTORO EUGENIO Istituto Mario Negri Milano

SHAH SOHRAB Memorial Sloan Kettering New York

SIGNORELLI DIEGO Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano

SPAGNOLETTI ANDREA Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

TROVÒ FRANCESCO Politecnico di Milano, DEIB

TRUHN DANIEL RWTH Aachen University, Aachen Germany

VERLINGUE LOÏC Centre Leon Berard Lyon

VIBERT JULIEN Gustave Roussy, Villejuif France

VISCARDI GIUSEPPE Azienda Ospedaliera Monaldi Cotugno Cto, Università degli Studi della Campania Luigi Vanvitelli, Napoli

UNDER THE AUSPICES OF

ASCO®

ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.*



INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER
Connecting Thoracic Cancer Scientists



ASSOCIAZIONE ITALIANA ONCOLOGIA MEDICA



UNITY IS STRENGTH



WITH THE UNCONDITIONAL SPONSORSHIP OF

PLATINUM SPONSOR



GOLD SPONSOR



SILVER SPONSOR



SCIENTIFIC PROVIDER AND CONGRESS ORGANIZER



Events srl

Via Lorenzo Lotto 9, 60019 Senigallia (AN)
www.events-communication.com
segreteria@events-communication.com
Ph. +39 071 7930220 Fax. +39 071 9252094



2nd edition

ARTIFICIAL INTELLIGENCE FOR ONCOLOGY

PRESIDENT OF THE CONFERENCE
ARSELA PRELAJ

MILAN, ITALY
MAY 10th 2024
& ONLINE



Sistema Socio Sanitario



PRESIDENT OF THE CONFERENCE

Arsela Prelaj, MD, PhD Candidate
Medical Oncologist and PhD student in Bioengineering and Artificial Intelligence
Politecnico di Milano
Thoracic Oncology Unit, Medical Oncology Department 1
Fondazione IRCCS Istituto Nazionale Tumori, Milano
Member of the ESMO Working Group on Real World Data and Digital Health

SCIENTIFIC COMMITTEE

Filippo de Braud, Fondazione IRCCS Istituto Nazionale Tumori, Milano

Alessandra Pedrocchi, **Francesco Trovò**, **Vanja Miskovic**
Politecnico di Milano, DEIB

SCIENTIFIC SECRETARIAT

Giovanni Scoazec, **Leonardo Provenzano**
Fondazione IRCCS Istituto Nazionale Tumori, Milano

General Information

CONGRESS VENUE

Aula Magna, *Fondazione IRCCS Istituto Nazionale Tumori*
Via Giacomo Venezian, 1 20133 Milano

VIRTUAL CONFERENCE

<https://www.events-fad.com/>

REGISTRATION

Registration is free of charge.
You may register for IN-PERSON OR ONLINE-ONLY ACCESS
www.events-communication.com/event/ai2024

OFFICIAL LANGUAGE AND TIME

The official language is English
The official Time is Central European Summer Time (CEST), UTC +2

CME CREDITS

CME accreditation (valid for Italian participants only) for: Medical Doctor, Chemist, Pharmacist, Biologist, Physician, Nurse.

CME credits RES: 4,9 - CME credits FAD: 10,5

Italian CME credits will be granted to those participants who attend at least 90% of scientific works, fill in the questionnaire assessment of perceived quality and duly fill in the evaluation questionnaires answering correctly 75% of the questions.

Overview

AI methodologies have been applied to medical research for years, and have recently made an impactful entrance in oncology more specifically. AI broadly speaking consists in a set of techniques allowing computers to emulate human intelligence, employing algorithms created for the analyses and the design of either predictions or conclusions based on the analysis of big datasets.

The latter is especially important for cancer research considering the critical mass of data available for analysis and that standard analysis methods fail to exploit to its fullest potential. This is particularly the case for multiomics data, with their high variation in nature, format or storage.

The proper and effective and integration of these novel methodologies into the standards of clinical – but also basic and translational – research could prove to be an important leap forward for oncology research. Hence, this event will have two core training objectives.

The first will be to ease the clinical and research community into the field of AI methodologies themselves, still misunderstood or not known to its full potential – from a general overview of the most frequently used ML/DL methods and Explainable AI to a deep dive in novel data platforms and repository structures integrating these approaches in their design. This will allow clinicians to identify the value of AI models for their trials and studies, making the volume of patient - and tumor-related data valuable and more fully exploitable; as well as biologists to assess its potential in tumor biology to discover new biomarkers and mechanisms.

The second main endpoint will be to demonstrate not only the possibilities offered by the inclusion of AI models in standard practice, but really to present some concrete and innovative activities where they are already being successfully implemented. The focus is to demonstrate in particular the value of AI for both its predictive power and for the possibilities it opens up for the discovery of both new biomarkers and of new molecules targeting specific tumors. In particular, one section will be focused on the translational field and the synergy between AI-powered multiomic data analysis and clinical research, with regards to cancer

immunotherapy, for example metastatic lung cancer. In this context, we will showcase and discuss ongoing projects, including I3LUNG, along with other initiatives focused on the diagnostic and treatment pathways optimization for lung cancer patients. These projects involve collaboration among research institutes, academia, and private companies. As the AI research field is evolving at a rapid pace, the event will be topped off by a session offering perspectives already going beyond the current state of the art and providing insights into the Artificial Intelligence of tomorrow – how it could be involved as full-fledged actor in clinical decision-making.

FORMAT

The event is set to be a full-day program. The speakers will have a diverse background to reflect the spectrum of Artificial Intelligence research (and beyond), from Artificial Intelligence engineering experts, to clinicians and translational researchers, and hybrid figures such as clinical Artificial Intelligence specialists. The attendance is expected to mirror this variety, along with participants with a more specific background in imaging and pathology.

ABSTRACT SUBMISSION CLOSED

Abstract submission is now closed.
The results of the abstract submission will be available on 04th March. Check your emails!

TOPIC AREAS:

1. Cancer screening with AI
2. Image diagnosis (radiomics and/or digital pathology)
3. Multiomics and/or Multimodal Integration with AI
4. Treatment prediction and Selection with AI and explainability
5. Special Section (AI legal-ethical frameworks, Innovative platforms and Cognitive sensing and wearable devices)

SUBMISSION DEADLINES:

31th January 2024 submission deadline
04th March 2024 outcome notifications

Scientific Program

08:30 POSTER SESSION

09:30 Welcome
Arsela Prelaj
Gustavo Galmozzi *President Fondazione IRCCS Istituto Nazionale dei Tumori*
Carlo Nicora *General Director Fondazione IRCCS Istituto Nazionale dei Tumori*
Giovanni Apolone *Scientific Director Fondazione IRCCS Istituto Nazionale dei Tumori*
Filippo de Braud *Director Dpt. of Oncology and Hemato-Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori*
Bruno Aratri *President IPOP Onlus*

09:50 Introduction
Massimo Di Maio *President-elect of AIOM*

session 1

BACKGROUND ON AI METHODOLOGIES AND THEIR USE IN THE CLINICAL PRACTICE

Chairs: **Francisco Sanchez Vega**, **Monica Ganzinelli**, **Francesco Trovò**

10:00 Machine, Deep Learning and Reinforcement Learning in medicine
Marcello Restelli

10:20 Explainable AI for RWD, genomics and gaps in images
Vanja Miskovic

10:40 Deep Learning applied to Genomics and Transcriptomics
Julien Vibert

11:00 Discussion

session 2

AI AND IMAGING: CLINICAL PRACTICE APPLICATION AND FUTURE DIRECTIONS

Chairs: **Andrea Spagnoletti**, **Alessandro Cicchetti**, **Giacomo Boracchi**

11:20 Integration of radiomics in clinical practice for screening and diagnosis
Mireia Crispin Ortuzar

11:40 The use of radiomics in prediction: treatment outcomes and toxicity
Raquel Pérez-Lopez

12:00 Integration of digital pathology in clinical practice for screening and diagnosis
Jakob Nikolas Kather

12:20 The use of digital pathology in prediction: treatment outcomes and toxicity
Alexander T. Pearson

12:40 Discussion

13:00 Lunch Break **POSTER SESSION**

session 3

AI FOR OMICS AND MULTIMODAL DATA ANALYSIS

Chairs: **Alessandra Pedrocchi**, **Arsela Prelaj**, **Luca Agnelli**

14:00 Multimodal integration: from methodology to its successful application
Sohrab Shah

14:20 SHARED TALK Molecular Tumor Board and the role of AI: the oncologist and AI-expert point of view
Filippo de Braud, **Loic Verlingue**

14:45 Drug discovery using virtual AI lab - Special lecture
Marina Chiara Garassino

15:05 Discussion

session 4

DATA STORAGE AND ITS REGULATORY FRAMEWORK

Chairs: **Sokol Kosta**, **Emilia Ambrosini**, **Laura Mazzeo**

15:25 Bridging the Gap: Federated Learning as a Catalyst for Collaborative Development of AI Models
Daniel Truhn

15:45 Digital therapeutics: clinical applications in oncology
Eugenio Santoro

16:05 AI and the MDR: between compliance and liability
Francesca Gennari

16:25 Discussion

16:40 Coffee Break **POSTER SESSION**

session 5

SPECIAL SESSION AND PROJECTS

Chairs: **Giuseppe Lo Russo**, **Claudia Proto**, **Diego Signorelli**

17:20 Accelerating Clinical Trials with AI-powered medical platforms for personalized dosing and Digital Twins
Dean Ho

17:40 Updates on the I3LUNG Horizon Europe Project
Leonardo Provenzano

17:50 Patients Decision Aid using AI tools
Dario Monzani

18:00 Discussion

session 6

AWARDS (NO CME SESSION)

Chairs: **Giuseppe Viscardi**, **Alessandro De Toma**, **Roberto Ferrara**

18.10 Introduction

18:15 Deep Learning-Based Tool for Detection and Discrimination of Breast Microcalcification on Mammography
Filippo Pesapane

18:20 Modelling toxicity after prostate cancer radiotherapy using genetically guided Voxel-Based Analysis
Nicola Rares Franco

18:25 Best poster award

The winner

18:30 Farewell and take-home messages
Arsela Prelaj